Albert Bourla, Pfizer CEO (Matthew Busch/Bloomberg via Getty Images)
May 19, 2022 02:25 PM EDT
Pharma

Pfiz­er delves in­to di­ver­si­ty-fo­cused clin­i­cal tri­al part­ner­ship

Paul Schloesser

Associate Editor

Just a few hours ago, Pfiz­er and dig­i­tal ther­a­peu­tics out­let Side­kick Health an­nounced a prod­uct launch in the next step of a pre-ex­ist­ing part­ner­ship. And …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times